KR101491927B1 - Composition for preventing or treating atopic dermatitis comprising colored potato peel as an active ingredient - Google Patents

Abstract

The present invention relates to a composition for preventing or treating atopic dermatitis containing an extract of colored potato peel as an active ingredient. More specifically, the present invention relates to: an external application, an oral formulation, an intravenous injection agent for preventing, treating, or alleviating atopic dermatitis; and a method for producing the same. According to the present invention, the extract of the colored potato peel reduces an IgE content in the blood, a thymic stromal lymphopoietin level (TSLP), and a TH2 cytokine level. The extract alleviates atopic dermatitis in a mouse having atopic dermatitis. Therefore, the composition can be advantageously used for an agent for preventing or treating atopic dermatitis. Peel waste generated when colored potatoes are processed can be used as a functional material.

Description

TECHNICAL FIELD [0001] The present invention relates to a composition for preventing or treating atopic dermatitis,

The present invention relates to a composition for preventing or treating atopic dermatitis, comprising a color potato skin extract as an active ingredient, more specifically, to an external preparation for oral use, an intravenous injection, and a preparation method for prevention, treatment or improvement of atopic dermatitis.

In 1925, Coca described for the first time the tendency of dermatitis, asthma and fever fever to appear in foods and respiratory organisms as atopy. Atopic diseases include atopic dermatitis, asthma, allergic rhinitis, allergic conjunctivitis and the like. The incidence of atopic dermatitis is rapidly increasing worldwide due to environmental pollutants and the prevalence rate is 20% of the total population. Patients with atopic dermatitis suffer from poor quality of life due to daily life constraints and socially an economic burden on treatment. Therefore, measures to manage atopy are urgent. Atopic dermatitis is a recurrent chronic skin disease with severe itching that starts in infancy or childhood and is a very common skin disease with family history. Symptoms begin in early childhood, especially about 2 months after birth. About 50% of these occur before 2 years of age and most of them develop symptoms before 5 years of age. . In some patients, symptoms may be alleviated or cured naturally with growth, and more than half of the infantile patients develop before 2 years of age. The appearance and distribution of skin lesions are characterized by pruritus (itching), dry skin and characteristic eczema. In infancy, it begins with eczema on the spreading side of the face and limbs, but it appears in the form of eczema on the part where the arm bends and the bending part behind the knee characteristically grows. In adults, lichenification of thickening skin appears, and eczema often develops on the face, chest, and nape of the limbs in comparison to the pediatric period.

Atopy usually involves allergic reactions. In particular, atopic dermatitis is not only a skin disease but also an allergic march such as allergic asthma and rhinitis. However, the precise cause and mechanism of atopic dermatitis has not yet been clarified, and thus a suitable therapeutic drug that can be cured has not been developed. Currently, antihistamines, steroids, and immunomodulators are used as treatments for atopic dermatitis. It is usually used for the relief of inflammation and immune reaction, and steroid-based immunosuppressive drugs are used. However, when they are shortened or terminated, the symptoms may be rapidly deteriorated. Secondarily, corticosteroid insufficiency, diabetes, , Hirsutism, alopecia, and coloration, and especially cataracts in children. Steroid ointments result in significant side effects such as thinning or atrophy of the skin, stretching of blood vessels, and folliculitis. Non-steroidal immunomodulators Elidel, pimecrolimus cream and Protopic (tacrolimus, FK506) ointment were developed as a substitute for steroid ointment, Throat and other sensitive skin, and has grown rapidly to 30% of the total atopic dermatitis market. However, recently, the risk of cancer-induced calcineurin inhibitor is raised. In patients younger than 16 years old, only low-dose use is recognized. In children younger than 2 years old, the use of low concentration is not recognized. . Other atopic treatments include antihistamines, severe short-term corticosteroids and topical medications, skin ultraviolet light therapy, and interferon therapy, but most of them have a mild improvement, to be. Therefore, it is urgently necessary to develop therapeutic and preventive drugs which have fewer side effects than existing therapeutic agents and exhibit high efficacy.

One of the world's four major food crops, potatoes ( Solanum tuberosum L.) has been a major source of carbohydrates. It is grown in more than 130 countries around the world because of its short growth period, high production per unit area, and relatively high environmental adaptability. Rice, wheat, soybeans, and corn (Park et al., 2009).

In terms of nutritional physiology, it contains a large amount of vitamins, carotenoids and minerals. It has been reported that more than 90% of the phenolic compound, chlorogenic acid, is present in the bark. In terms of medicine, it also plays a big role in prevention of adult diseases caused by modernized eating habits of modern people. From ancient times, it has been called "potato", and in the Hunan Medicinal Magazine of the oriental medicine, the middle of the navel is seen from the bottom of the middle chin, and the middle part of the navel is seen, and the spleen and stomach are strengthened The presence of anti-inflammatory activity was recorded. It has cold properties and it was also used to lower the fever, but when I put on the burner when I got burned, I could get the effect of sinking quickly. Civil medicine effects that have been passed on to oriental medicine and oral medicine have been proved through various studies of medicinal chemical and physiological activity (Jo et al., 2003)

Potatoes grown in the world today are predominantly white or light yellow. However, in the natural world, there are also a variety of color potatoes containing cyanidin-based natural pigments such as red and purple due to the diversity of genes involved in tuberous color formation (Park et al., 2007). Carotenoids and anthocyanins in color potatoes have not only increased consumers' preference due to their unique color, but also have a powerful antioxidant effect of these pigments, which may change the consumption pattern of potatoes (Park et al. , 2008; Park et al., 2009). On the other hand, the physiological activity effects of cyanidin and carotene compounds, which are natural colorants of color potato, have been reported as various studies. (Park et al., 2008; Hwang et al., 2010), antimutagenic and anticancer effects (Kang and Jeong, 2008) are typical results of antioxidant and antihypertensive activities related to anthocyanin compounds.

As the demand for color potatoes grows, it is expected that the processed food industry such as peel potatoes and color potato chips will develop. In this case, a lot of shells are generated as waste in the process, and it is necessary to prepare a utilization plan.

In recent years, the authors have reported various physiological activities of color-fleshed potatoes (Kang and Jeong, 2008; Park et al. al ., 2008). The present inventors confirmed that the present invention exhibits a specific physiological activity effect not only in the flesh portion of the potatoes but also in the outer portion of the potatoes. The solvent extracts and fractions of the envelope were examined in LPS-induced RAW 264.7 cells (NO, PGE ₂ ) and the inflammatory mediators (iNOS, COX-2) that induce it. Thus, the present invention has been accomplished by confirming the possibility that the shell waste generated in the processing of color potato can be used as a functional material for prevention or treatment of atopy.

The inventors of the present invention confirmed that the color potato skin extract exhibited the effect of alleviating atopic symptoms, lowering the blood IgE level, TSLP (thymic stromal lymphopoietin) level, and reducing the blood TH2 cytokine level, The present invention solves the above-mentioned problems by providing a composition for prevention or treatment of atopy, which comprises a skin extract as an active ingredient.

The color potato envelope extract according to the present invention not only reduces blood IgE level and TSLP (thymic stromal lymphopoietin) level but also reduces blood TH2 cytokine level, and also has an effect of alleviating atopic symptoms in mice induced by actual atopy It can be usefully used as an atopy preventive or therapeutic agent, and the shell waste generated in the processing of color potato can be utilized as a functional material.

Figure 1 is a reference scoring index picture of an NC / Nga mouse.
FIG. 2 shows the results of sensory evaluation for atopic dermatitis induced by Dfb.
FIG. 3 shows the results of tissue staining and measurement of mast cell levels for atopic dermatitis induced by Dfb.
FIG. 4 shows the results of analysis of Th2 cytokines (IL-4, IL-5, IL-13) against Dfb-induced atopic dermatitis symptoms.
FIG. 5 is a graph showing the results of analysis of IgE and TSLP for Dfb-induced atopic dermatitis symptoms.

The present invention relates to a pharmaceutical composition for preventing or treating atopic dermatitis, which contains a color potato skin extract as an active ingredient.

In one embodiment of the present invention, the color potato envelope extract may use a shell of 5 mm or less in thickness of the color potato.

In one aspect, it keolreogam as according to the invention is independent (Solanum tuberosum L. cv Jayoung), Hongyoung, and Sumi varieties can be used, and more specifically, self-help can be used.

In one embodiment of the present invention, the color potato envelope extract has an effect of reducing blood IgE level and TSLP (thymic stromal lymphopoietin) level, decreasing the level of TH2 cytokine in blood, and alleviating the symptom according to atopy .

In one embodiment of the present invention, the color potato envelope extract may be extracted with water, C _{1 -4} lower alcohol or a mixed solvent thereof, and more particularly ethanol.

In one embodiment according to the present invention, the pharmaceutical composition may be formulated in the form of an oral preparation, injectable preparation or external preparation.

      In another embodiment according to the present invention, an oral preparation or injection for preventing or improving atopic dermatitis containing color potato skin extract as an active ingredient may be provided.

More specifically, the pharmaceutical composition may be in the form of tablets, pills, powders, granules, capsules, suspensions, solutions, emulsions, syrups, sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, Lt; RTI ID = 0.0 > formulations < / RTI >

In one embodiment of the present invention, the color potato skin extract is administered in an amount of 0.001 mg to 1000 mg / day, or 0.001 mg to 100 mg / day, or 0.01 mg to 10 mg / day to an individual in need of prevention or treatment of atopy. mg / day is administered to a warm-blooded animal weighing 75 kg, thereby preventing or treating atopy.

The dosage of the color potato skin extract for use in the present invention depends on a variety of factors such as the availability and duration of action of the active ingredient, the mode of administration, the sex of the warm-blooded animal, the age, weight, It can be different. The particular route of administration and dosage may be selected by the attending physician / veterinarian according to the characteristics of the subject to be administered, such as age, weight, disease state, physical condition, and the like.

The route of administration of the composition may be administered via any conventional route so long as it can reach the target tissue. The composition of the present invention may be administered orally, intraperitoneally, intravenously, intramuscularly, subcutaneously, intradermally, intranasally, intracisternally, rectally, Do not. The composition may also be administered by any device capable of transferring the active agent to the target cell.

In one embodiment of the invention, the pharmaceutical preparations for oral administration may be in unit dosage forms and ampoules, such as, for example, dragees, tablets, pills, powders, granules or capsules. They are prepared in a manner known per se, for example by conventional mixing, granulating, sugar-making, dissolving or lyophilizing processes. For example, pharmaceutical preparations for oral administration can be prepared by mixing the active ingredient with a solid carrier, granulating the mixture, adding appropriate additives if necessary, and then formulating the mixture or granules in the form of tablets or dragees .

Suitable carriers are in particular fillers such as sugars such as lactose, saccharose, mannitol or sorbitol, cellulose preparations and / or calcium phosphates such as tricalcium phosphate or calcium hydrogenphosphate, and binders such as corn, Gelatin, tragacanth, methylcellulose and / or polyvinylpyrrolidone, and, if necessary, disintegrants such as the above-mentioned starches, carboxymethyl starch, crosslinked polyvinylpyrrolidone Money, agar, or alginic acid or its salt, such as sodium alginate.

Additives are in particular flow-adjusting agents and lubricants, for example silicic acid, talc, stearic acid or its salts, such as magnesium stearate or calcium, and / or polyethylene glycol. A suitable coating, which may be gastric juice resistant, is provided to the dragee core, and in particular a concentrated sugar solution, optionally containing the gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and / or titanium dioxide in a suitable organic solvent or solvent mixture, Or a solution of a suitable cellulose preparation such as acetylcellulose phthalate or hydroxypropylmethylcellulose phthalate may be used in order to use a locker solution or to form a coating resistant to gastric juice.

Other orally administrable pharmaceutical preparations include capsules, dry-filled capsules made of gelatin, and soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The dry-filled capsules may contain the active ingredient in the form of particles, for example in the form of a filler, such as lactose, a binder such as starch, and / or a lubricant, for example talc or magnesium stearate, You may. In soft capsules, the active ingredient may be dissolved or suspended in a suitable liquid, such as a fatty oil, paraffin oil or liquid polyethylene glycol, to which a stabilizing agent may be added.

Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Parenteral formulations may be injections which are effective in a variety of ways, such as intravenous, intraarterial, intramuscular, intraperitoneal, intranasal, intradermal, subcutaneous, preferably intravenous. Such liquids are preferably isotonic aqueous solutions or suspensions which may be prepared from a lyophilized preparation containing the active ingredient alone or in combination with a pharmaceutically acceptable carrier. The pharmaceutical preparations can be sterilized and / or contain additives such as preserving, stabilizing, wetting and / or emulsifying agents, solubilizing agents, salts for controlling osmotic pressure and / or buffers.

Specific examples of the non-aqueous solvent and the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao paper, laurin, glycerogelatin and the like.

In one embodiment of the present invention, the color potato skin extract according to the present invention may be administered in combination / combination with other drugs for prevention or treatment of atopy. Accordingly, the present invention also encompasses a method of treating an atopic patient comprising combination therapy with a color potato skin extract and a different atopic preventive / therapeutic agent.

In one embodiment according to the present invention, the composition for external application may be selected from the group consisting of cream, gel, ointment, emulsion, suspension, spray, and transdermal patching agent, but is not limited thereto.

In one embodiment of the present invention, the external preparation may be applied in an amount of 0.1 to 50 mg per day, specifically, in an amount of 1 to 20 mg per day, and may be administered once to several times a day, Lt; RTI ID = 0.0 > 1-3 < / RTI > It can be applied until atopic dermatitis symptoms improve.

In another aspect of the present invention, there is provided a cosmetic composition for preventing or improving atopic dermatitis, which comprises a color potato skin extract as an active ingredient.

In one aspect of the present invention, the cosmetic composition may be at least one selected from the group consisting of atopic soap, a cleansing foam, a cleansing cream, a cleansing water, a bath agent, a skin lotion, a skin softener, a skin toner, a lotion, a cream, an essence, an astringent, But is not limited to, any one or more formulations selected from the group consisting of a spray, a shampoo, a rinse, a treatment, a body cleanser, a pack, a massage, a face powder, a compact, a foundation, a two-way cake and a makeup base.

In one aspect of the present invention, the cosmetic composition may be manufactured into a formulation selected from the group consisting of atopic soap, cleansing foam, cleansing cream, cleansing water and bath agent.

When the formulation of the present invention is a paste, a cream or a gel, an animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide .

When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, / Propane or dimethyl ether.

When the formulation of the present invention is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.

In the case where the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tragacanth.

When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component is selected from aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters.

In the present invention, the term "containing as an active ingredient" means a dose range that provides improvement, prevention, or treatment of atopic dermatitis. The dose range may vary depending on the severity and formulation, Age, body weight, and constitution of the subject.

In the present invention, "atopic dermatitis" is used to mean any disease classified as atopic dermatitis in the art regardless of whether it occurs directly or indirectly. In general, atopic dermatitis is classified into infantile atopic dermatitis, infantile atopic dermatitis, adult atopic dermatitis, and mothergic atopic dermatitis according to the onset period or the object of the invention. In the present invention, atopic dermatitis includes all types of atopic dermatitis .

In the present invention, "when having atopic dermatitis" means a state in which the infected area of the skin is changed by atopic dermatitis. Such a condition includes both a condition considered as a skin disease and a condition not regarded as a skin disease.

In the present invention, "treatment" is a result of application of the pharmaceutical composition of the present invention to atopic dermatitis site, which includes partial cure, improvement and alleviation of atopic dermatitis symptom as well as cure of atopic dermatitis symptom.

In the present invention, "prevention" means that the pharmaceutical composition of the present invention is applied to skin, particularly atopic dermatitis, so as to prevent or prevent atopic dermatitis symptom on the skin so that atopic dermatitis symptom does not occur in advance.

In the present invention, "improvement" is meant to include alleviation, prevention or treatment of symptoms.

In the present invention, the term "active ingredient" means an ingredient exhibiting activity alone or together with a carrier which is not active per se.

The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount.

The term "pharmaceutically effective amount " as used herein means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment or amelioration, and an effective dosage level will vary depending on the species and severity, age, sex, The activity of the compound, the sensitivity to the drug, the time of administration, the route of administration and the rate of release, the duration of the treatment, factors including co-administered drugs, and other factors well known in the medical arts.

The term "individual" as used herein refers to all animals, including humans, who have already developed or are capable of developing atopic disease, and by administering to a subject a composition comprising the color potato skin extract according to the present invention, Prevention and improvement.

Hereinafter, embodiments of the present invention will be described in more detail. However, the embodiments according to the present invention can be modified into various other forms, and the scope of the present invention is not limited by the following embodiments.

< Example >

Example 1. Preparation of color potato skin extract - Preparation and standardization of 70% ethanol extract

Color potato varieties, self-help ( Solanum tuberosum L. cv Jayoung) from the Highland Agriculture Research Center (HARC) of the National Institute of Rural Development. The color potatoes used as samples were cut into small pieces with a thickness of <5 mm and a color potato shell was used as a sample. It was freeze-dried and stored at -70 ° C. The slice (7 kg) was pulverized and extracted three times with 30 L of 70% aqueous EtOH. The extracts were mixed and concentrated under the condition of 40 in a vacuum concentrator to obtain a 70% ethanol extract (641 g).

Two kinds of phenolic acids, caffeic acid and chlorogenic acid were isolated from the ethanol extracts by silica gel and ODS column chromatography and were identified by comparison with genuine samples.

Waters 2695 separations module equipped with a Waters 2996 photodiode array detector (320 nm) and a shiseido capcellpak C18 (250 mm 4.6 mm ID, 5 μm, Shiseido, Tokyo, Japan) , MA, USA).

The mobile phase consisted of 0.4% phosphoric acid (solvent A) and methanol (solvent B) and was separated at a flow rate of 0.7 mL / min.

isocratic elution 95% A / 5% B, 0-5 min;

linear gradient 95% A / 5% B → 50% A / 50% B, 5-55 min;

isocratic elution 50% A / 50% B, 55-65 min;

linear gradient 50% A / 50% B → 95% A / 5% B 65-70 minutes;

Isocratic elution 95% A / 5% B, 70-80 min.

2.5 mg of EtOH extract was dissolved in distilled water (2.5 mL) and ACN (2.5 mL). 10 [mu] L aliquot was filtered through a 0.45 [mu] m membrane-filter and loaded into the HPLC system. Two kinds of phenolic acid, caffeic acid and chlorogenic acid were eluted at 21.7 minutes and 19.9 minutes, respectively. The caffeic acid and chlorogenic acid contents in the EtOH extract were analyzed to be 1.31 and 8.60 mg / g, respectively.

< Experimental Example >

1. Preparation of experimental animals

The experimental animals used in this experiment were NC / Nga mice at 5 weeks of age. They were fed from the Central Laboratory Animals and were weighed (22 ± 3 g) Lt; / RTI &gt; During the experimental period, solid feed and water were freely taken, and the temperature of the breeding room (21 ± 1 ℃) and humidity (50 ± 5%) were kept constant.

On the day before the start of the experiment, the entire back of the back of the animal from the lower part of the ear to the upper part of the tail was cleanly removed with a mouse hair clipper (JC-4005, JOAS Elec. CO., Korea). This animal experiment was carried out in accordance with the provisions of the Animal Experiment Ethics Committee under the prior deliberation of the Sangji University Laboratory Animal Ethics Committee.

2. Induction of atopic dermatitis and sample treatment

The back of the NC / Nga mouse and the upper part of the auricle were completely removed by using an epilator, and hair was completely removed by using a hair removal cream. The application area was sprayed with 4% SDS aqueous solution (150 μL, used from the second AD ointment application) to remove skin fat and cuticle layer. It was completely dried for about 2-3 hours. 100 mg was uniformly applied to the back of the ear with the AD induced ointment (Dfb) on a flat stick.

3. Sensory Evaluation (Clinical Score)

The dermatitis of NC / Nga mice used a clinical visual assessment method commonly used in atopic dermatitis. Sensory evaluation was performed immediately before Dfb treatment, during treatment, immediately before drug administration, during drug administration and at the end of drug administration. Scoring of dermatitis by sensory evaluation was conducted by two or more persons who had experience in the experiment, respectively, and the results were decided in consultation. Especially after the drug treatment was finished, pictures were taken and kept.

The visual evaluation results were expressed as the sum of the scores obtained by evaluating each of the following five items. The evaluation items are divided into Erythema, Pruritus & Dry Skin, Edema & escoriation, Erosion, and Lichenification, (1), severity (2), and severity (3). Scoring of dermatitis was conducted by two or more subjects who had experience in the experiment, respectively, and decided by consultation. Especially after the drug treatment was finished, pictures were taken and kept.

4. Quantification of IgE in serum

On the end of the experiment, the blood was collected from the heart of the mouse, and the serum was separated by centrifugation at 5,000 rpm and 4 ° C for 3 minutes. The mixture was stored in a -70 ° C freezer until it was used in the experiment.

The concentrations of serum IgE in Nc / Nga mice were measured using an ELISA Kit For Mouse (Shibayagi Co., Ltd, Japan). IgE was quantified by the method of IgE ELISA Kit For Mouse (Shibayagi Co., Ltd, Japan). All reagents were used at room temperature immediately after preparation. After washing the plate three times with washing buffer, 50 μL of IgE standard solution or sample solution (5 μL of sample + 45 μL of buffer) was loaded into each well, lightly mixed with a microplate shaker, (20 ~ 25 ° C), reacted and washed three times with buffer. 50 [mu] L of biotin-conjugated anti-IgE antibody was loaded into each well and lightly mixed with a microplate shaker. After incubation for 2 hours at room temperature, the plate was washed three times with wash buffer, and HRP - Add 50 μL of avidin solution, mix gently with a microplate shaker, incubate for one hour at room temperature, react, add 50 μL of chromagenic substrate solution, lightly mix with microplate shaker, incubate for 20 minutes at room temperature The reaction was stopped by adding 50 μL of a reaction stopper to each well. The absorbance was measured at 450 nm within 30 minutes after discoloration was stopped.

5. Tissue Dyeing and Evaluation

After the experiment, mice were sacrificed and the ear tissues were removed and fixed with 10% neutral formalin fixation. The tissue was embedded in paraffin to produce a paraffin block. Tissue sections were trimmed with a microtome (Microm-HM325) by trimming the paraffin block to a thickness of about 10 μm, and then sectioned to a thickness of 3 to 4 μm. The obtained tissue sections were deparaffinized with xylene and the functional phase [100% Alcohol (3 min) → 90% Alcohol (3 min) → 80% Alcohol (3 min) → 70% Alcohol (3 min) → DW (10 min.)] Followed by a dehydration step [70% alcohol (3 min.)] Followed by staining [Harris' hematoxylin (dipping) → 80% alcohol (dipping) → 95% alcohol (dipping) → 100% alcohol (dipping) → 100% alcohol dipping] and the transparent stage [xylene (3 minutes) → xylene (3 minutes)] And then canada balsam was used to observe it.

In addition, the degree of inflammation was assessed by the thickness of the induced tissue epidermis, infiltration of mast cells, neutrophils and lymphocytes infiltration, and fibroblast proliferation and collagen layer hyperplasia Histology experiments were performed. The mast cells in the tissues were observed by staining with Toludine blue.

6. Statistical Analysis

The measurement results were compared by means of one-way ANOVA. Statistical significance was P <0.05 or less than 5%. In other words, the null hypothesis that there is no difference between the experimental group and the control group is rejected and the P value is set to be valid when the probability of supporting the contradiction hypothesis is less than 5%.

<Experimental Methods and Results>

1. Sensory evaluation of symptoms of Dfb-induced atopic dermatitis

Atopic symptoms were observed on the skin in 8 groups at weekly intervals in 3 groups of normal, Dfb, control and color potatoes.

The skin of the normal group (NOR) was clean, and various atopic symptoms such as erythema, edema, swelling, sloughing, and flaring were conspicuous in the atopic control group (CON). In all of the color potato application groups, Was significantly suppressed. (See Fig. 2)

2. Tissue staining for symptoms of Dfb-induced atopic dermatitis

Dfb mice were exposed to atopy by sensitization and attack. After the experiment, mice were sacrificed and the ear tissue was removed and fixed in 10% formalin solution. The tissues were stained with hematoxylin and eosin stain to determine the degree of ulceration, thickness of induced tissue epidermis, mast cell infiltration, neutrophil and lymphocyte infiltration, and fibroblast proliferation and collagen layer Abnormal proliferation was observed. Subcutaneous subcutaneous, dermis, and epidermis were uniformly arranged in the normal group, and no ulceration, hemorrhage, or inflammation was observed. I did. (See Fig. 3)

The control group, CON, showed severe severe ulceration and hemorrhage in the tissue photographs and was observed sporadically in the tissues of inflammation caused by neutrophils infiltration, and inflammation due to neutrophil infiltration spread to the skin Respectively. Severe severe fibroblast proliferation and collagen layer hyperplasia were also observed. In addition, purulent inflammation by bacterial colonies was also observed.

In color photocoagulation group, ulcer and inflammation were observed in infiltration of mild neutrophil and lymphocyte in some individuals, but no abnormal growth of collagen layer was observed.

In conclusion, the degree of ulceration was not observed in the normal group but severe severe ulceration was observed in the atopy-induced group. In color potato skin application group, slight ulcers were observed.

The inflammatory findings of fibroblast proliferation and collagen layer hyperplasia were not observed in the normal group (NOR), but fibroblast proliferation and collagen layer abnormal proliferation were not observed , And atopic induction group (CON), severe severe fibroblast proliferation and abnormal collagen layer growth were observed. No fibroblast proliferation or abnormal collagen layer proliferation was observed in all of the color potato application groups.

Also, mast cell counts in the microscopic field of view at 400x were found to be 53 in the normal group (NOR) and 82 in the atopic group (CON). 58 skin lesions were observed in the oil - skin - treated group and showed more improvement than the atopic group (CON).

3. Analysis of Th2 cytokines for Dfb-induced atopic dermatitis symptoms

The concentrations of IL-4, IL-5 and IL-13 were measured by ELISA and qRT-PCR in Th2 cytokines produced by tissues such as mice that induced atopy by Dfb sensitization and attack.

IL-4, IL-5 and IL-13 were significantly increased in the atopy-induced control group (CON). In the color potato skin application group, it was significantly lower than the atopic control group. (See Fig. 4)

4. Analysis of IgE and TSLP (thymic stromal lymphopoietin) for the symptoms of Dfb-induced atopic dermatitis

The concentrations of IgE and TSLP in sera from mice induced by atopy by Dfb sensitization and challenge were measured by ELISA.

The concentration of IgE was 3.85 pg / ml in the normal group (NOR) and 42.91 pg / ml in the atopic control group (CON). And 11.76 pg / ml in color potato skin application group.

The concentration of TSLP was 3.73 pg / ml in the normal group (NOR) and 39.96 pg / ml in the atopic control group (CON). And 6.97 pg / ml in the color potato skin application group, compared to the atopy control group. (See Fig. 5)

Hereinafter, production examples of each preparation according to the present invention will be illustrated. The following Preparation Examples are intended to aid the understanding of the practice of the present invention and do not imply that the process for preparing a formulation according to the present invention is limited to the following Preparation Examples.

Production Example 1. Preparation of powder

Color potato skin extract 10mg

Sucrose 100 mg

Talc 10mg

The above components are powdered and mixed, and filled in an airtight container to prepare a powder.

Production Example 2. Preparation of tablets

Color potato skin extract 10mg

Starch 100mg

Sucrose 100 mg

Magnesium stearate 2 mg

The tablets are prepared by mixing the above components according to a conventional method for producing tablets and then tableting them.

Preparation Example 3. Preparation of capsules

Color potato skin extract 10mg

Crystalline cellulose 3 mg

Lactose 15mg

1 mg of magnesium stearate

The above components are mixed according to a conventional method for preparing a capsule, and then filled in a gelatin capsule to prepare a capsule.

Production Example 4. Preparation of Granules

Color potato skin extract 10mg

Soybean extract 50mg

200 mg of glucose

Starch 500 mg

After mixing the above components, 100 mL of 30% ethanol is added and the mixture is dried at 60 ° C to form granules, which are filled in a capsule to prepare granules.

Production Example 5. Preparation of a pellet

Color potato skin extract 10mg

Lactose 1,500mg

1,500 mg of glycerin

Starch 980 mg

After mixing the above components, the mixture is prepared to be 4 g per one ring according to a conventional method for producing a pellet.

Production Example 6. Preparation of injection

Color potato skin extract 10mg

180 mg mannitol

Sterile sterilized water for injection 2,970mg

Na ₂ HPO _{4 12} H ₂ O 30 mg

(2 mL) per 1 ampoule according to a conventional injection preparation method.

Production Example 7. Production of liquid agent

Color potato skin extract 10mg

10,000 mg per isomerization

Mannitol 5,000 mg

Purified water quantity

Dissolving the above components in purified water according to a usual liquid preparation method, adding an appropriate fragrance, filling the bottle and sterilizing it.

Production Example 8. Preparation of Soap

330 mL of water and 175 g of NaOH were mixed and completely dissolved, and then 10 mg of color potato skin extract was added to the mixture while gradually adding thereto for about 30 minutes. The mixture was allowed to dry in a shady, windy environment until dry.

Production Example 9. Preparation of Bath Agent

10 mg of color potato extract was added to about 60 ° C, and then a salt solution was prepared by adding sun salt to evaporate the water. The solution was cooled at room temperature and freeze-dried by rapid freezing. The lyophilized solid was powdered to prepare a bath agent.

Production Example 10. Production of cleansing lotion

Colored Potato Skin Extract 0.001 v / v% Sodium ethylenediaminetetraacetate 0.02 Paraoxybenzoic acid methyl 0.2 glycerin 4 Sodium Hyruronic Acid 2 Propylene glycol 3 Carbomer 5 Cetearyl alcohol 0.7 Glyceryl stearate 0.5 Sheer butter One P-hydroxybenzoic acid profile 0.1 Macadamia nut oil One Sesquioleic acid 0.5 Glyceryl stearate One Polyoxyethylene sorbitan monooleate 2 Polydensen 5 Mineral oil 20 Dimethicone 5 Stearyl dimethicone 2 Triethanolamine 0.05 Spices Suitable amount Pigment Suitable amount Purified water Balance

The above ingredients were used to prepare the cleansing lotion according to the conventional method in the field of cosmetic production.

Preparation Example 11. Preparation of skin

Colored Potato Skin Extract 0.001 v / v% Paraoxybenzoic acid methyl 0.2 Sodium ethylenediaminetetraacetate 0.02 1,3-butylene glycol 0.02 Allantoin 3 Sodium hyaluronic acid seed 5 Carbomer 0.1 Cetostearyl alcohol 0.7 P-hydroxybenzoic acid profile 0.1 Sorbitan olivate 1.5 Soy lecithin 0.2 Dimethicone 0.2 Cetyl octanoate 0.2 Sheer butter 0.2 Sodium placrylate 3 Triethanolamine 0.1 Imidazolidinyl urea 0.3 Spices Suitable amount Pigment Suitable amount Purified water Balance

These ingredients were used to make the skin according to the conventional method in the field of cosmetics for making a skin.

Preparation Example 12. Preparation of serum

Colored Potato Skin Extract 0.001 v / v% Jojoba 5 Black Sesame 2 Sweet almond 3 This malting wax One Vitamin E One glycerin 2 Hyaluronic acid One Marine Elastin One Purified water Balance

The above ingredients were used to prepare according to the conventional method in the field of cosmetic production for the production of serum.

Production Example 13. Production of lotion

Colored Potato Skin Extract 0.001 v / v% Paraoxybenzoic acid methyl 0.2 Sodium ethylenediaminetetraacetate 0.02 1,3-butylene glycol 0.02 Allantoin 3 Sodium hyaluronic acid seed 5 Carbomer 0.1 Cetostearyl alcohol 0.7 P-hydroxybenzoic acid profile 0.1 Sorbitan olivate 1.5 Soy lecithin 0.2 Dimethicone 0.2 Cetyl octanoate 0.2 Sheer butter 0.2 Sodium placrylate 3 Triethanolamine 0.1 Imidazolidinyl urea 0.3 Spices Suitable amount Pigment Suitable amount Purified water Balance

The above ingredients were used to prepare according to conventional methods in the field of cosmetics for the manufacture of lotions.

Production Example 14. Preparation of Essence

Colored Potato Skin Extract 0.001 v / v% Allantoin 0.05 Sodium ethylenediaminetetraacetate 0.02 Triethanolamine 0.2 Sodium Hyaluronic Acid 7 Imidazolidinyl urea 0.15 Sodium polyacrylate 0.4 Carbomer 0.2 ethanol 3 Polyoxyethylene sorbitan monostearate 0.2 Paraoxybenzoic acid methyl 0.2 Spices Suitable amount Pigment Suitable amount Purified water Balance

The above ingredients were used to prepare according to a conventional method in the field of cosmetic preparation for essence production.

Production Example 15. Production of Cream

Colored Potato Skin Extract 0.001 v / v% Sodium ethylenediaminetetraacetate 0.02 Allantoin 0.1 glycerin 5 Paraoxybenzoic acid methyl 0.2 Sodium Hyaluronic Acid 6 Carbomer 0.1 Cetostearyl alcohol 1.7 Polydensen 2 Squalane 2 P-hydroxybenzoic acid profile 0.1 Butylene glycol dicaprylate 3 Cetyl octanoate 5 Microcrystalline lead 0.1 Triethylpentanediol 0.1 Sheer butter 0.2 Sorbitan olivate 0.3 Cyclomethicone 0.3 Stearyl dimethicone 0.5 Imidazolidinyl urea 0.15 Spices Suitable amount Pigment Suitable amount Purified water Suitable amount

These ingredients were used to prepare the cream according to the conventional method in the field of cosmetic production.

Production Example 16. Pack Production

Colored Potato Skin Extract 0.001 v / v% Sodium ethylenediaminetetraacetate 0.02 Betaine 3 Glyceryl polymethacrylate 2 Allantoin 0.1 Sodium Hyruronic Acid 2 glycerin 3 Dipropylene glycol 5 Paraoxybenzoic acid methyl 0.2 Polyvinyl alcohol 10 Polyoxyethylene sorbitan monooleate 0.9 Sesquioleic acid 0.3 Jojoba ester 2 Cetearyl alcohol 1.5 Petrolatum 0.5 Spices Suitable amount Pigment Suitable amount Purified water Suitable amount

The ingredients were prepared according to the conventional method in the field of cosmetic production for pack manufacture.

Production Example 17. Production of Massage Cream

Colored Potato Skin Extract 0.001 v / v% Purified water Suitable amount glycerin 4.0 vaseline 3.5 Triethanolamine 0.5 Liquid paraffin 24.5 Squalane 2.5 Wax 2.1 Tocopheryl acetate 0.1 Cava Paul 1.0 Sorbitan sesquioleate 3.1 incense a very small amount antiseptic a very small amount

The ingredients were used to make the usual methods in the field of cosmetic manufacturing for the production of massage cream.

Preparation Example 18. Preparation of make-up base

Colored Potato Skin Extract 0.001 v / v% Purified water Suitable amount Coated silica One Silica 10 Titanium dioxide 8 Zinc oxide 3 Pigment One Plate powder Balance

These ingredients were used to make the makeup base according to the conventional method in the field of cosmetic production.

Production Example 19. Production of Powder Fact

Colored Potato Skin Extract 0.001 v / v% Purified water Suitable amount Mica 15 Titanium dioxide 7 Silicone oil 3 Ester oil 3 Pigment Suitable amount Spices Suitable amount Talc Balance

The powder facts were prepared according to a conventional method in the field of cosmetic production for the powder fact using the above-mentioned components.

Production Example 20. Two-way cake production

Colored Potato Skin Extract 0.001 v / v% Purified water Suitable amount Mica 15 Titanium dioxide 12 Silicone oil 3 Ester oil 5 Pigment Suitable amount Spices Suitable amount Talc Balance

The ingredients were used to make the usual methods in the field of cosmetics for the manufacture of two-way cakes.

Claims (11)

A pharmaceutical composition for preventing or treating atopic dermatitis, which comprises an outer coat extract having a color potato thickness of 5 mm or less as an active ingredient.
delete The method according to claim 1,
The color is independent potato (Solanum tuberosum L. cv Jayoung). &lt; / RTI &gt;
The method according to claim 1,
The pharmaceutical composition for preventing or treating atopic dermatitis of the present invention is characterized in that the color potato envelope extract reduces blood IgE level and TSLP (thymic stromal lymphopoietin) level and decreases blood TH2 cytokine level.
The method according to claim 1,
Wherein the color potato envelope extract is extracted with water, C _{1 -4} lower alcohol or a mixed solvent thereof.
The method according to claim 1,
A pharmaceutical composition for preventing or treating atopic dermatitis, wherein the color potato skin extract is extracted with ethanol.
The method according to claim 1,
Wherein the pharmaceutical composition is formulated in the form of an oral preparation, injectable preparation or external preparation.
8. The method of claim 7,
Wherein the external preparation is selected from the group consisting of a cream, a gel, an ointment, an emulsion, a suspension, a spray, and a transdermal patching agent.
8. The method of claim 7,
The pharmaceutical composition for preventing or treating atopic dermatitis according to claim 1, wherein the external preparation is applied in an amount of 0.1 to 50 mg per day.
A cosmetic composition for preventing or ameliorating atopic dermatitis comprising a skin extract having a thickness of 5 mm or less of color potato as an active ingredient.
11. The method of claim 10,
The cosmetic composition may be at least one selected from the group consisting of atopic soap, cleansing foam, cleansing cream, cleansing water, bath agent, skin lotion, skin softener, skin toner, lotion, cream, essence, Wherein the cosmetic composition is prepared from one or more formulations selected from the group consisting of a body lotion, a body cleanser, a pack, a massager, a face powder, a compact, a foundation, a two-way cake and a makeup base.

Images